Cargando…

Risk Factors Associated with Endometrial Pathology in Premenopausal Breast Cancer Patients Treated with Tamoxifen

PURPOSE: To evaluate factors associated with endometrial pathology during tamoxifen use in premenopausal breast cancer (BC) patients. MATERIALS AND METHODS: We reviewed the medical records of premenopausal BC patients treated with tamoxifen who underwent endometrial biopsy with or without hysterosco...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Maria, Piao, Jinlan, Jeon, Myung Jae
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Yonsei University College of Medicine 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105402/ https://www.ncbi.nlm.nih.gov/pubmed/32233174 http://dx.doi.org/10.3349/ymj.2020.61.4.317

Ejemplares similares

Endometrial polyp surveillance in premenopausal breast cancer patients using tamoxifen
por: Jeon, Se Jeong, et al.
Publicado: (2017)

Risk of Endometrial Polyps, Hyperplasia, Carcinoma, and Uterine Cancer After Tamoxifen Treatment in Premenopausal Women With Breast Cancer
por: Ryu, Ki-Jin, et al.
Publicado: (2022)

Risk of Endometrial Cancer and Frequencies of Invasive Endometrial Procedures in Young Breast Cancer Survivors Treated With Tamoxifen: A Nationwide Study
por: Choi, Soojeong, et al.
Publicado: (2021)

Effect of Tamoxifen and Raloxifene on the Proliferative Activity of the Breast Epithelium in Premenopausal Women
por: Lucato, Miliana T, et al.
Publicado: (2015)

Ovarian cancer risk in premenopausal and perimenopausal women treated with Tamoxifen: a case–control study
por: Swerdlow, A J, et al.
Publicado: (2007)

Endometrial Surveillance in Tamoxifen and Letrozole Treated Breast Cancer Patients
por: AlZaabi, Adhari, et al.
Publicado: (2021)

Inactivation of the retinoblastoma tumour suppressor pathway in premenopausal breast cancer is associated with resistance to tamoxifen
por: Lehn, S, et al.
Publicado: (2009)

Prognostic Effects of Adjuvant Chemotherapy-Induced Amenorrhea and Subsequent Resumption of Menstruation for Premenopausal Breast Cancer Patients
por: Jeon, Se Jeong, et al.
Publicado: (2016)

Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic
por: Donnelly, L S, et al.
Publicado: (2014)

Endometrial thickness cut-off value by transvaginal ultrasonography for screening of endometrial pathology in premenopausal and postmenopausal women
por: Park, Yu Ran, et al.
Publicado: (2019)

Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer
por: Saladores, P, et al.
Publicado: (2015)

Premenopausal abnormal uterine bleeding and risk of endometrial cancer
por: Pennant, ME, et al.
Publicado: (2016)

Clinicopathological and molecular pathological characteristics in tamoxifen‑related endometrial cancer
por: Saeki, Harumi, et al.
Publicado: (2023)

Change in Estradiol Levels among Premenopausal Patients with Breast Cancer Treated Using Leuprolide Acetate 11.25 Milligrams 3-Month Depot and Tamoxifen
por: Lee, Young-jin, et al.
Publicado: (2020)

Agoraphobia and Follicle-Stimulating Hormone Levels between Tamoxifen and Goserelin versus Tamoxifen Alone in Premenopausal Hormone Receptor-Positive Breast Cancer: A 12-Month Prospective Randomized Study
por: Heo, Jung-Yoon, et al.
Publicado: (2017)

Lipidome of mammographic breast density in premenopausal women
por: Getz, Kayla R., et al.
Publicado: (2023)

Tamoxifen-induced ovarian hyperstimulation during premenopausal hormonal therapy for breast cancer in Japanese women
por: Yamazaki, Rena, et al.
Publicado: (2015)

Tamoxifen treatment in premenopausal breast cancer patients may be associated with ovarian overstimulation, cystic formations and fibroid overgrowth.
por: Cohen, I., et al.
Publicado: (1994)

Low Z‐4OHtam concentrations are associated with adverse clinical outcome among early stage premenopausal breast cancer patients treated with adjuvant tamoxifen
por: Helland, Thomas, et al.
Publicado: (2020)

Risk Factors for Premenopausal Breast Cancer in Bangladesh
por: Iqbal, Javaid, et al.
Publicado: (2015)

Impairment of endoxifen formation in tamoxifen‐treated premenopausal breast cancer patients carrying reduced‐function CYP2D6 alleles
por: Thorén, Linda, et al.
Publicado: (2020)

Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer
por: Lundgren, Katja, et al.
Publicado: (2008)

Tamoxifen with ovarian function suppression versus tamoxifen alone as an adjuvant treatment for premenopausal breast cancer: a meta-analysis of published randomized controlled trials
por: Yan, Shunchao, et al.
Publicado: (2015)

IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women
por: Joosten, Stacey E. P., et al.
Publicado: (2021)

Use of Low-Dose Tamoxifen to Increase Mammographic Screening Sensitivity in Premenopausal Women
por: Eriksson, Mikael, et al.
Publicado: (2021)

Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen
por: Brennan, Donal J, et al.
Publicado: (2011)

Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial
por: Lundgren, Christine, et al.
Publicado: (2023)

Randomized trial of medroxyprogesterone acetate for the prevention of endometrial pathology from adjuvant tamoxifen for breast cancer: SWOG S9630
por: Potkul, Ronald K, et al.
Publicado: (2016)

Combined effects of goserelin and tamoxifen on estradiol level, breast density, and endometrial thickness in premenopausal and perimenopausal women with early-stage hormone receptor-positive breast cancer: a randomised controlled clinical trial
por: Yang, H, et al.
Publicado: (2013)

Non-alcoholic fatty liver disease as a risk factor for female sexual dysfunction in premenopausal women
por: Lee, Jae Yeon, et al.
Publicado: (2017)

Molecular mechanisms of tamoxifen-associated endometrial cancer (Review)
por: HU, RONG, et al.
Publicado: (2015)

Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years
por: Brentnall, Adam R., et al.
Publicado: (2020)

A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis
por: Hong, Jin, et al.
Publicado: (2020)

Measurement of endometrial thickness in premenopausal women in office gynecology
por: Tsuda, Hiroshi, et al.
Publicado: (2017)

Effects of Tamoxifen on Endometrial Carcinogenesis in Mice
por: Niwa, Kenji, et al.
Publicado: (1998)

Ovarian hyperstimulation in premenopausal women during adjuvant tamoxifen treatment for endocrine-dependent breast cancer: A report of two cases
por: MADEDDU, CLELIA, et al.
Publicado: (2014)

Endometrial evaluation with transvaginal ultrasonography for the screening of endometrial hyperplasia or cancer in premenopausal and perimenopausal women
por: Kim, Min-Jeong, et al.
Publicado: (2016)

Associations of Breast Cancer Risk Factors with Premenopausal Sex Hormones in Women with Very Low Breast Cancer Risk
por: Houghton, Lauren C., et al.
Publicado: (2016)

Low grade endometrial stromal sarcoma in a premenopausal woman
por: Jetley, Sujata, et al.
Publicado: (2014)

Endometrial evaluation by ultrasonography, hysteroscopy and histopathology in cases of breast carcinoma on Tamoxifen therapy
por: Jindal, Alka, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_5bcbemvj4n5l9bkenb70jhikgs